

Theunis C Goosen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2106588/publications.pdf>

Version: 2024-02-01

55
papers

3,376
citations

172457

29
h-index

161849

54
g-index

55
all docs

55
docs citations

55
times ranked

3457
citing authors

#	ARTICLE	IF	CITATIONS
1	DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1201-1208.	3.3	870
2	In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies. <i>Drug Metabolism and Disposition</i> , 2010, 38, 448-458.	3.3	219
3	SILYBIN INACTIVATES CYTOCHROMES P450 3A4 AND 2C9 AND INHIBITS MAJOR HEPATIC GLUCURONOSYLTRANSFERASES. <i>Drug Metabolism and Disposition</i> , 2004, 32, 587-594.	3.3	180
4	Optimized Assays for Human UDP-Glucuronosyltransferase (UGT) Activities: Altered Alamethicin Concentration and Utility to Screen for UGT Inhibitors. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1051-1065.	3.3	135
5	Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions. <i>Pharmaceutical Research</i> , 2012, 29, 2860-2873.	3.5	122
6	Targeted Quantitative Proteomics for the Analysis of 14 UGT1As and -2Bs in Human Liver Using NanoUPLC-MS/MS with Selected Reaction Monitoring. <i>Journal of Proteome Research</i> , 2013, 12, 4402-4413.	3.7	111
7	Kinetics of Acetaminophen Glucuronidation by UDP-Glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential Implications in Acetaminophen-Induced Hepatotoxicity. <i>Chemical Research in Toxicology</i> , 2006, 19, 701-709.	3.3	109
8	pH-Sensitive Interaction of HMG-CoA Reductase Inhibitors (Statins) with Organic Anion Transporting Polypeptide 2B1. <i>Molecular Pharmaceutics</i> , 2011, 8, 1303-1313.	4.6	97
9	Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide. <i>Pharmaceutical Research</i> , 2013, 30, 1188-1199.	3.5	96
10	A Perspective on the Prediction of Drug Pharmacokinetics and Disposition in Drug Research and Development. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1975-1993.	3.3	89
11	Relative Contributions of Cytochrome CYP3A4 Versus CYP3A5 for CYP3A-Cleared Drugs Assessed In Vitro Using a CYP3A4-Selective Inactivator (CYP3cide). <i>Drug Metabolism and Disposition</i> , 2014, 42, 1163-1173.	3.3	79
12	Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 607-617.	4.7	75
13	Selective Mechanism-Based Inactivation of CYP3A4 by CYP3cide (PF-04981517) and Its Utility as an In Vitro Tool for Delineating the Relative Roles of CYP3A4 versus CYP3A5 in the Metabolism of Drugs. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1686-1697.	3.3	73
14	Physicochemical Property Space of Hepatobiliary Transport and Computational Models for Predicting Rat Biliary Excretion. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1527-1537.	3.3	66
15	Targeted Precise Quantification of 12 Human Recombinant Uridine-Diphosphate Glucuronosyl Transferase 1A and 2B Isoforms Using Nano-Ultra-High-Performance Liquid Chromatography/Tandem Mass Spectrometry with Selected Reaction Monitoring. <i>Drug Metabolism and Disposition</i> , 2013, 41, 2076-2080.	3.3	64
16	Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 459-472.	3.3	63
17	Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2). <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7173-7185.	6.4	61
18	Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin. <i>Drug Metabolism and Disposition</i> , 2013, 41, 966-974.	3.3	55

#	ARTICLE	IF	CITATIONS
19	Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 458-468.	2.4	51
20	Atorvastatin Glucuronidation Is Minimally and Nonselectively Inhibited by the Fibrates Gemfibrozil, Fenofibrate, and Fenofibric Acid. <i>Drug Metabolism and Disposition</i> , 2007, 35, 1315-1324.	3.3	50
21	Investigating the Enteroenteric Recirculation of Apixaban, a Factor Xa Inhibitor: Administration of Activated Charcoal to Bile Duct-Cannulated Rats and Dogs Receiving an Intravenous Dose and Use of Drug Transporter Knockout Rats. <i>Drug Metabolism and Disposition</i> , 2013, 41, 906-915.	3.3	49
22	Intestinal Targeting of Drugs: Rational Design Approaches and Challenges. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 776-802.	2.1	49
23	Inactivation of Cytochrome P450 2B1 by Benzyl Isothiocyanate, a Chemopreventative Agent from Cruciferous Vegetables. <i>Chemical Research in Toxicology</i> , 2000, 13, 1349-1359.	3.3	47
24	Mechanism-Based Pharmacokinetic Modeling to Evaluate Transporter-Enzyme Interplay in Drug Interactions and Pharmacogenetics of Glyburide. <i>AAPS Journal</i> , 2014, 16, 736-748.	4.4	47
25	Differential Effects of Naturally Occurring Isothiocyanates on the Activities of Cytochrome P450 2E1 and the Mutant P450 2E1 T303A. <i>Archives of Biochemistry and Biophysics</i> , 2001, 391, 99-110.	3.0	46
26	Establishing Transcriptional Signatures to Differentiate PXR, CAR, and AhR-Mediated Regulation of Drug Metabolism and Transport Genes in Cryopreserved Human Hepatocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 262-271.	2.5	46
27	Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity. <i>Drug Metabolism and Disposition</i> , 2017, 45, 1102-1112.	3.3	40
28	Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1285-1303.	3.3	39
29	In Vitro Kinetic Characterization of Axitinib Metabolism. <i>Drug Metabolism and Disposition</i> , 2015, 44, 102-114.	3.3	33
30	Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping. , 2021, 218, 107689.		28
31	Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: A bench-to-bedside case study on tissue selective drug distribution. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2725-2731.	2.2	27
32	Identification of potent, selective, CNS-targeted inverse agonists of the ghrelin receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5410-5414.	2.2	26
33	UDP-GLUCURONOSYLTRANSFERASE 2B7 IS THE MAJOR ENZYME RESPONSIBLE FOR GEMCABENE GLUCURONIDATION IN HUMAN LIVER MICROSOMES. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1349-1354.	3.3	25
34	Physicochemical characterization and solubility analysis of thalidomide and its N-alkyl analogs. <i>Pharmaceutical Research</i> , 2002, 19, 13-19.	3.5	24
35	Data Generated by Quantitative Liquid Chromatography-Mass Spectrometry Proteomics Are Only the Start and Not the Endpoint: Optimization of Quantitative Concatemer-Based Measurement of Hepatic Uridine-5â€²-Diphosphateâ€²-Glucuronosyltransferase Enzymes with Reference to Catalytic Activity. <i>Drug Metabolism and Disposition</i> , 2018, 46, 805-812.	3.3	19
36	Metabolites in Safety Testing Assessment in Early Clinical Development: A Case Study with a Glucokinase Activator. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1926-1939.	3.3	18

#	ARTICLE	IF	CITATIONS
37	Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2021, 49, 947-960.	3.3	17
38	Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate Constants. <i>Drug Metabolism and Disposition</i> , 2021, 49, 442-450.	3.3	15
39	Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Guidelines on Model Fitting and Recommendations on Time Course for In Vitro Cytochrome P450 Induction Studies Including Impact on Drug Interaction Risk Assessment. <i>Drug Metabolism and Disposition</i> , 2021, 49, 94-110.	3.3	14
40	Percutaneous delivery of thalidomide and its N-alkyl analogs. <i>Pharmaceutical Research</i> , 2002, 19, 434-439.	3.5	13
41	In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes. <i>Drug Metabolism and Disposition</i> , 2020, 48, 1350-1363.	3.3	12
42	Effect of oral contraceptives on the transport of chlorpromazine across the CACO-2 intestinal epithelial cell line. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2003, 56, 159-165.	4.3	10
43	Physiologically-Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co-Administration with the UGT Inhibitor Mefenamic Acid. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 127-136.	2.5	9
44	Drug-Drug Interaction After Single Oral Doses of the Furanocoumarin Methoxsalen and Cyclosporine. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 768-775.	2.0	8
45	Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(4-ethylbenzylthio)phenylsulfamoyl-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated receptor alpha. <i>Xenobiotica</i> , 2013, 43, 963-972.	1.1	8
46	Biosynthesis and Identification of Metabolites of Maraviroc and Their Use in Experiments to Delineate the Relative Contributions of Cytochrome P4503A4 versus 3A5. <i>Drug Metabolism and Disposition</i> , 2018, 46, 493-502.	3.3	8
47	Induction of human cytochrome P450 3A4 by the irreversible myeloperoxidase inactivator PF-06282999 is mediated by the pregnane X receptor. <i>Xenobiotica</i> , 2018, 48, 647-655.	1.1	8
48	Reactive Metabolite Trapping Studies on Imidazo- and 2-Methylimidazo[2,1-b]thiazole-Based Inverse Agonists of the Ghrelin Receptor. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1375-1388.	3.3	7
49	Insights into the Novel Hydrolytic Mechanism of a Diethyl 2-Phenyl-2-(2-aryloxy)methyl Malonate Ester-Based Microsomal Triglyceride Transfer Protein (MTP) Inhibitor. <i>Chemical Research in Toxicology</i> , 2012, 25, 2138-2152.	3.3	4
50	Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1505-1518.	2.0	4
51	Chemical stabilities and biological activities of thalidomide and its N-alkyl analogs. <i>Pharmaceutical Research</i> , 2002, 19, 1232-1235.	3.5	3
52	Response to the Comment on the Article "Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions". <i>Pharmaceutical Research</i> , 2013, 30, 1469-1470.	3.5	3
53	6-Chloro-5-[4-(1-Hydroxycyclobutyl)Phenyl]-1-Indole-3-Carboxylic Acid is a Highly Selective Substrate for Glucuronidation by UGT1A1, Relative to 17β -Estradiol. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1836-1846.	3.3	2
54	Investigation of CYP3A induction by PF-05251749 in early clinical development: comparison of linear slope physiologically based pharmacokinetic prediction and biomarker response. <i>Clinical and Translational Science</i> , 2022, 15, 2184-2194.	3.1	2

#	ARTICLE	IF	CITATIONS
55	Undesired versus designed enzymatic cleavage of linkers for liver targeting. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1144-1147.	2.2	1